Trials / Completed
CompletedNCT04522089
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Adimmune Corporation · Industry
- Sex
- All
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.
Detailed description
The objectives of this phase I study are: 1. to evaluate the safety profile of the AdimrSC-2f vaccine, and 2. to assess the immunogenicity of the AdimrSC-2f vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AdimrSC-2f | AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant. |
Timeline
- Start date
- 2020-08-24
- Primary completion
- 2020-11-20
- Completion
- 2021-05-06
- First posted
- 2020-08-21
- Last updated
- 2022-05-24
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04522089. Inclusion in this directory is not an endorsement.